Literature DB >> 60347

Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate.

J Geller, J Albert, D Lopez, S Geller, G Niwayama.   

Abstract

5 alpha-Dihydrotestosterone (DHT) and androstanediols (diols) have been measured in human prostate tissue. DHT levels in surgical specimens of prostate from 8 patients with BPH averaged 5.6 +/- 0.93 S.E. ng/g and were significantly greater than (P less than 0.01) values of 2.1 +/- 0.32 S.E. ng/g in 6 normal prostates obtained post-mortem from males less than 50 yrs old. Androstanediols averaged 2.3 +/- 0.35 S.E. ng/g in the BPH specimens compared to values of 10.2 +/- 2.4 S.E. ng/g in the normal prostates (P less than 0.01). This significantly higher (P less than 0.001) ratio of diols/DHT in the normal (5.1 +/- 0.93 S.E.) compared to the BPH prostate (0.45 +/- 0.08 S.E.) suggests that a decrease in 3-hydroxysteroid oxido-reductase, which converts DHT to diol, may be an important clue to the pathogenesis of BPH.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 60347     DOI: 10.1210/jcem-43-3-686

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

2.  Biosynthesis of catalytically active rat testosterone 5 alpha-reductase in microinjected Xenopus oocytes: evidence for tissue-specific differences in translatable mRNA.

Authors:  Y Farkash; H Soreq; J Orly
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 3.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

4.  Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog.

Authors:  R J Moore; J M Gazak; J F Quebbeman; J D Wilson
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

Review 5.  Androgen action in prostate function and disease.

Authors:  Partha P Banerjee; Subhadra Banerjee; Terry R Brown; Barry R Zirkin
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

6.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.

Authors:  M Ohtawa; H Morikawa; J Shimazaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

7.  Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal.

Authors:  P C Walsh; G M Hutchins; L L Ewing
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia.

Authors:  I Morimoto; A Edmiston; R Horton
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

Review 9.  Prostate tissue androgens: history and current clinical relevance.

Authors:  Leonard S Marks; Elahe A Mostaghel; Peter S Nelson
Journal:  Urology       Date:  2008-05-27       Impact factor: 2.649

10.  Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate.

Authors:  C B Brendler; S J Berry; L L Ewing; A R McCullough; R C Cochran; J D Strandberg; B R Zirkin; D S Coffey; L G Wheaton; M L Hiler; M J Bordy; G D Niswender; W W Scott; P C Walsh
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.